347 related articles for article (PubMed ID: 8527479)
1. Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein.
Yang Y; Vanin EF; Whitt MA; Fornerod M; Zwart R; Schneiderman RD; Grosveld G; Nienhuis AW
Hum Gene Ther; 1995 Sep; 6(9):1203-13. PubMed ID: 8527479
[TBL] [Abstract][Full Text] [Related]
2. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes.
Ory DS; Neugeboren BA; Mulligan RC
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11400-6. PubMed ID: 8876147
[TBL] [Abstract][Full Text] [Related]
3. A new system for stringent, high-titer vesicular stomatitis virus G protein-pseudotyped retrovirus vector induction by introduction of Cre recombinase into stable prepackaging cell lines.
Arai T; Matsumoto K; Saitoh K; Ui M; Ito T; Murakami M; Kanegae Y; Saito I; Cosset FL; Takeuchi Y; Iba H
J Virol; 1998 Feb; 72(2):1115-21. PubMed ID: 9445007
[TBL] [Abstract][Full Text] [Related]
4. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells.
Burns JC; Friedmann T; Driever W; Burrascano M; Yee JK
Proc Natl Acad Sci U S A; 1993 Sep; 90(17):8033-7. PubMed ID: 8396259
[TBL] [Abstract][Full Text] [Related]
5. Generation of high-titer pseudotyped retroviral vectors with very broad host range.
Yee JK; Friedmann T; Burns JC
Methods Cell Biol; 1994; 43 Pt A():99-112. PubMed ID: 7823872
[TBL] [Abstract][Full Text] [Related]
6. Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir.
Howard BD; Boenicke L; Schniewind B; Henne-Bruns D; Kalthoff H
Cancer Gene Ther; 2000 Jun; 7(6):927-38. PubMed ID: 10880025
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent transduction of vesicular stomatitis virus G protein-pseudotyped retrovirus vector into human solid tumor cell lines and murine fibroblasts.
Arai T; Takada M; Ui M; Iba H
Virology; 1999 Jul; 260(1):109-15. PubMed ID: 10405362
[TBL] [Abstract][Full Text] [Related]
8. Development of inducible EIAV-based lentiviral vector packaging and producer cell lines.
Stewart HJ; Leroux-Carlucci MA; Sion CJ; Mitrophanous KA; Radcliffe PA
Gene Ther; 2009 Jun; 16(6):805-14. PubMed ID: 19262613
[TBL] [Abstract][Full Text] [Related]
9. Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system.
Chen ST; Iida A; Guo L; Friedmann T; Yee JK
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10057-62. PubMed ID: 8816750
[TBL] [Abstract][Full Text] [Related]
10. Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor.
Ghani K; Garnier A; Coelho H; Transfiguracion J; Trudel P; Kamen A
Biotechnol Bioeng; 2006 Nov; 95(4):653-60. PubMed ID: 16947907
[TBL] [Abstract][Full Text] [Related]
11. Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein.
Bartz SR; Vodicka MA
Methods; 1997 Aug; 12(4):337-42. PubMed ID: 9245614
[TBL] [Abstract][Full Text] [Related]
12. Pseudotransduction of hepatocytes by using concentrated pseudotyped vesicular stomatitis virus G glycoprotein (VSV-G)-Moloney murine leukemia virus-derived retrovirus vectors: comparison of VSV-G and amphotropic vectors for hepatic gene transfer.
Liu ML; Winther BL; Kay MA
J Virol; 1996 Apr; 70(4):2497-502. PubMed ID: 8642678
[TBL] [Abstract][Full Text] [Related]
13. In vitro cell-free conversion of noninfectious Moloney retrovirus particles to an infectious form by the addition of the vesicular stomatitis virus surrogate envelope G protein.
Abe A; Chen ST; Miyanohara A; Friedmann T
J Virol; 1998 Aug; 72(8):6356-61. PubMed ID: 9658075
[TBL] [Abstract][Full Text] [Related]
14. Transduction efficiency of pantropic retroviral vectors is controlled by the envelope plasmid to vector plasmid ratio.
Chen Y; Miller WM; Aiyar A
Biotechnol Prog; 2005; 21(1):274-82. PubMed ID: 15903266
[TBL] [Abstract][Full Text] [Related]
15. Lack of superinfection interference in retroviral vector producer cells.
Vogt B; Roscher S; Abel B; Hildinger M; Lamarre A; Baum C; von Laer D
Hum Gene Ther; 2001 Mar; 12(4):359-65. PubMed ID: 11242528
[TBL] [Abstract][Full Text] [Related]
16. A new-generation stable inducible packaging cell line for lentiviral vectors.
Farson D; Witt R; McGuinness R; Dull T; Kelly M; Song J; Radeke R; Bukovsky A; Consiglio A; Naldini L
Hum Gene Ther; 2001 May; 12(8):981-97. PubMed ID: 11387062
[TBL] [Abstract][Full Text] [Related]
17. Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors.
Chinnasamy N; Chinnasamy D; Toso JF; Lapointe R; Candotti F; Morgan RA; Hwu P
Hum Gene Ther; 2000 Sep; 11(13):1901-9. PubMed ID: 10986562
[TBL] [Abstract][Full Text] [Related]
18. Production of vesicular stomatitis virus G glycoprotein (VSV-G) pseudotyped retroviral vectors.
Lo HL; Yee JK
Curr Protoc Hum Genet; 2007 Jan; Chapter 12():Unit 12.7. PubMed ID: 18428407
[TBL] [Abstract][Full Text] [Related]
19. RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors.
Bell AJ; Fegen D; Ward M; Bank A
Exp Biol Med (Maywood); 2010 Oct; 235(10):1269-76. PubMed ID: 20876083
[TBL] [Abstract][Full Text] [Related]
20. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
